BREAKING
Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 20 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 21 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 22 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 4 days ago Zoom Communications Q4 2025 Earnings Results 5 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 5 days ago Synopsys Q1 2026 Earnings Results 5 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 5 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 5 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 6 days ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 20 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 21 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 22 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 4 days ago Zoom Communications Q4 2025 Earnings Results 5 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 5 days ago Synopsys Q1 2026 Earnings Results 5 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 5 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 5 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 6 days ago
ADVERTISEMENT
AlphaGraphs

Vertex Pharmaceuticals reports 14% growth in Q1 revenue: Infographic

Vertex Pharmaceuticals (NASDAQ: VRTX) reported first-quarter 2021 financial results after the regular market hours on Thursday. The pharmaceutical firm reported Q1 revenue of $1.72 billion, up 14% year-over-year and above the Wall Street projection. Net income of $2.98 per share was also above the target that analysts had anticipated. VRTX shares were down 0.4% immediately […]

April 29, 2021 1 min read

Vertex Pharmaceuticals (NASDAQ: VRTX) reported first-quarter 2021 financial results after the regular market hours on Thursday. The pharmaceutical firm reported Q1 revenue of $1.72 billion, up 14% year-over-year and above the Wall Street projection. Net income of $2.98 per share was also above the target that analysts had anticipated. VRTX shares were down 0.4% immediately […]

· April 29, 2021

Vertex Pharmaceuticals (NASDAQ: VRTX) reported first-quarter 2021 financial results after the regular market hours on Thursday. The pharmaceutical firm reported Q1 revenue of $1.72 billion, up 14% year-over-year and above the Wall Street projection. Net income of $2.98 per share was also above the target that analysts had anticipated.

VRTX shares were down 0.4% immediately following the announcement. The stock has fallen 7% since the beginning of this year.

Vertex Pharma Q1 2021 earnings

Looking forward to listening to management / analyst comments on the results? Stay tuned here for Vertex Pharmaceuticals Q1 earnings call transcript

Prior performance

ADVERTISEMENT